First Time Loading...

Aerie Pharmaceuticals Inc
NASDAQ:AERI

Watchlist Manager
Aerie Pharmaceuticals Inc Logo
Aerie Pharmaceuticals Inc
NASDAQ:AERI
Watchlist
Price: 15.25 USD 0.07%
Updated: May 3, 2024

Aerie Pharmaceuticals Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aerie Pharmaceuticals Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Aerie Pharmaceuticals Inc
NASDAQ:AERI
Operating Income
-$26.7m
CAGR 3-Years
48%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$23.4B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$10.5B
CAGR 3-Years
14%
CAGR 5-Years
6%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Operating Income
$13.1B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
-3%
Merck & Co Inc
NYSE:MRK
Operating Income
$6.6B
CAGR 3-Years
-10%
CAGR 5-Years
-11%
CAGR 10-Years
-2%
Eli Lilly and Co
NYSE:LLY
Operating Income
$10.3B
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
6%

See Also

What is Aerie Pharmaceuticals Inc's Operating Income?
Operating Income
-26.7m USD

Based on the financial report for Sep 30, 2022, Aerie Pharmaceuticals Inc's Operating Income amounts to -26.7m USD.

What is Aerie Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
25%

Over the last year, the Operating Income growth was 80%. The average annual Operating Income growth rates for Aerie Pharmaceuticals Inc have been 48% over the past three years , 25% over the past five years .